Mexico

Tuberculosis profile

Population 2018: 126 million

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>29 (22–37)</td>
<td>23 (18–29)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>2.8 (2.1–3.6)</td>
<td>2.2 (1.7–2.8)</td>
</tr>
<tr>
<td>MDR/RR-TB incidence**</td>
<td>0.95 (0.7–1.2)</td>
<td>0.75 (0.56–0.98)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>1.9 (1.9–1.9)</td>
<td>1.5 (1.5–1.5)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>0.59 (0.43–0.78)</td>
<td>0.47 (0.34–0.62)</td>
</tr>
</tbody>
</table>

Estimated proportion of TB cases with MDR/RR-TB, 2018

- % tested with rapid diagnostics at time of diagnosis: <1%
- % with known HIV status: 89%
- % pulmonary: 80%
- % bacteriologically confirmed***: 83%
- % children aged 0-14 years: 3%
- % women: 36%
- % men: 61%

Total cases notified: 24 096

Universal health coverage and social protection

- TB treatment coverage (notified/estimated incidence), 2018: 80% (63–100)
- TB case fatality ratio (estimated mortality/estimated incidence), 2018: 9% (7–11)

Notified cases by age group and sex, 2018

- Females
- Males
- Incidence

Drug-resistant TB care, 2018

- % of bacteriologically confirmed TB cases tested for rifampicin resistance***
  - New cases: <1%
  - Previously treated cases: 11%

Laboratory-confirmed cases*

- MDR/RR-TB: 298, XDR-TB: 2

Patients started on treatment**

- MDR/RR-TB: 245, XDR-TB: 1

MDR/RR-TB cases tested for resistance to second-line drugs: 246

Treatment success rate and cohort size

- New and relapse cases registered in 2017: 77% 22 757
- Previously treated cases, excluding relapse, registered in 2017: 51% 763
- HIV-positive TB cases registered in 2017: 58% 2 512
- MDR/RR-TB cases started on second-line treatment in 2016: 68% 77
- XDR-TB cases started on second-line treatment in 2016: 100% 1

TB preventive treatment, 2018

- % of HIV-positive people (newly enrolled in care) on preventive treatment: 1%
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: 100%

TB financing, 2019

- National TB budget (US$ millions): 11
- Funding source: 100% domestic, 0% international, 0% unfunded

---

* Ranges represent uncertainty intervals

** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Calculated for pulmonary cases only

* Includes cases with unknown previous TB treatment history

** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

Generated: 2020-04-11

Data: www.who.int/tb/data